News

GRIT Bio Welcomes Jie Jia, Ph.D. as New COO to Drive Growth

GRIT Bio Welcomes Jie Jia, Ph.D. as New COO to Drive Growth

GRIT Bio's New Chapter with Jie Jia, Ph.D.

Shenzhen GRIT Biotechnology Co., Ltd., a prominent player in the field of cell therapy, is excited to announce the appointment of Jie Jia, Ph.D., as the company's Chief Operating Officer (COO).

With over two decades of experience in strategic leadership within the biopharmaceutical sector, Dr. Jia's track record speaks volumes. His prior role at CARsgen Therapeutics saw him successfully navigate the company from its startup phase to becoming a public entity by establishing its U.S. operations.

Strategic Vision for Future Growth

Dr. Jia has a robust background that combines academia and industry, having contributed as an assistant professor at notable institutions. He earned his Bachelor’s degree in Biochemistry from Sichuan University and holds a Ph.D. in Biochemistry and Molecular Biology from the Chinese Academy of Sciences, along with an MBA in Leadership and Digital Marketing from Youngstown State University.

The Chairman and CEO of GRIT Bio, Dr. Yarong Liu, expressed their enthusiasm, stating, "We are delighted to welcome Dr. Jia. His extensive experience in leading biotech companies and developing markets internationally aligns perfectly with GRIT Bio's vision. We are confident that his leadership will advance our mission of innovating cell therapies for patients with solid tumors."

Advancing Cell Therapy Innovations

In response to his appointment, Dr. Jia reflected on the exciting opportunities at GRIT Bio. He noted, "With remarkable scientists and proprietary platforms, GRIT Bio has developed numerous pioneering TIL projects with great potential, maintaining a leading global position in therapy development. I am eager to advance collaborations that will contribute to our future growth and success."

Founded in 2019, GRIT Bio focuses on immunotherapy solutions for oncology patients, backed by a solid R&D pipeline in tumor-infiltrating lymphocyte (TIL) therapies. The company has successfully completed multiple funding rounds with support from distinguished venture capitalists.

Breaking New Ground in Clinical Trials

GT101, a groundbreaking injectable product by GRIT Bio, is the first TIL therapy to enter registrational clinical trials and is currently undergoing pivotal Phase II studies. Additionally, GRIT Bio's GT201 injectable, the first TIL therapy featuring a membrane-bound IL-15 complex, has received clearance for Investigational New Drug (IND) applications in both the U.S. and China.

GRIT Bio is equipped with cutting-edge R&D platforms, including the StemTexp® TIL expansion platform, StaViral® virus-transfected cell lines, and the ImmuT Finder® for immune modulator discovery. Leveraging these technologies, GRIT Bio is at the forefront of developing next-generation gene-edited TIL therapies aimed at addressing solid tumors effectively.

Looking Ahead: The Path to Innovation

With a commitment to pioneering efforts in the biopharmaceutical arena, GRIT Bio’s vision extends beyond mere treatment; it aims to offer new hope and potential breakthroughs to cancer patients worldwide. The company is committed to leveraging international technology and resources to bring transformative therapies to the forefront of oncology.

About GRIT Bio

GRIT Bio, established in 2019, is dedicated to developing advanced treatments for cancer through innovative cell therapy approaches. As a company founded on rigorous scientific principles and a commitment to patient care, GRIT Bio seeks to improve outcomes for those battling solid tumors through cutting-edge medical advancements.

Frequently Asked Questions

What is GRIT Bio known for?

GRIT Bio specializes in innovative cell therapies for oncology, focusing on tumor-infiltrating lymphocyte (TIL) therapies.

Who is the new COO of GRIT Bio?

Dr. Jie Jia has recently been appointed as the Chief Operating Officer of GRIT Bio, bringing extensive industry experience.

What initiatives is GRIT Bio pursuing?

The company is advancing its R&D pipeline and conducting pivotal clinical trials for its TIL therapies.

When was GRIT Bio founded?

GRIT Bio was founded in 2019, focusing on developing innovative treatments for cancer patients.

What are the key products of GRIT Bio?

Notable products include GT101 and GT201, which are advanced therapies currently in clinical trials.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

International Isotopes Enhances Growth with New Facilities

Updated Category News Views 139

International Isotopes Expands Its Operational Footprint International Isotopes, Inc. (OTCQB: INIS) has announced a significant expansion of its operational capabilities with a strategic land acquisition and a new facility lease agreement. This initiative is part of a broader strategy aimed at enhancing the Company's footprint in the radiopharmaceuticals sector. Strategic...

Continue Reading
Humana Achieves Top Honors in Customer Experience Again

Updated Category News Views 80

Humana Excels in Customer Experience for Four Straight Years Humana has once again secured the top position in customer experience among health insurers, according to a recent survey conducted by Forrester. This marks the fourth consecutive year that Humana has achieved this prestigious recognition, reaffirming its commitment to delivering exceptional service and care to...

Continue Reading
BrainStorm Cell Therapeutics Presents Insights into ALS Treatment

Updated Category News Views 128

BrainStorm Cell Therapeutics Webinar on ALS Treatments BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a prominent innovator in adult stem cell therapeutics for neurodegenerative diseases, will be hosting an insightful webinar on current developments in treating amyotrophic lateral sclerosis (ALS). This event is designed to provide essential updates and perspectives...

Continue Reading
Celebrating Excellence: The 2024 Employer Branding Awards Unveiled

Updated Category News Views 235

Overview of the Employer Branding Creativity Awards The "2024 Employer Branding Creativity Awards" organized by the Employer Branding Institute, recognized 75 exemplary companies for their innovative contributions to employer branding. Sponsored by Jaguar Land Rover China, this prestigious event not only celebrates creativity but also demonstrates the rising influence of...

Continue Reading
Battery Recycling Market Expected to Hit $77.1 Billion by 2034

Updated Category News Views 210

Battery Recycling Market Overview The battery recycling market is gaining remarkable traction worldwide, projected to soar to $77.1 billion by 2034. This forecast represents a significant growth trajectory from a valuation of $26.9 billion in 2024, indicating a compound annual growth rate (CAGR) of 11.2% from 2025 to 2034. Impact of Government Regulations Government...

Continue Reading